These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 1461092)
1. A study of T1-weighted 31phosphorus MR-spectroscopy from patients with focal and diffuse liver disease. Brinkmann G; Melchert UH Magn Reson Imaging; 1992; 10(6):949-56. PubMed ID: 1461092 [TBL] [Abstract][Full Text] [Related]
2. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Menon DK; Sargentoni J; Taylor-Robinson SD; Bell JD; Cox IJ; Bryant DJ; Coutts GA; Rolles K; Burroughs AK; Morgan MY Hepatology; 1995 Feb; 21(2):417-27. PubMed ID: 7843715 [TBL] [Abstract][Full Text] [Related]
3. [31P-MR spectroscopy of liver diseases with reference to variable pulse recovery times]. Brinkmann G; Melchert UH; Lalk G; Heller M Rofo; 1993 Nov; 159(5):412-8. PubMed ID: 8219133 [TBL] [Abstract][Full Text] [Related]
4. The total entropy for evaluating 31P-magnetic resonance spectra of the liver in healthy volunteers and patients with metastases. Brinkmann G; Melchert UH; Lalk G; Emde L; Link J; Muhle C; Steffens JC; Heller M Invest Radiol; 1997 Feb; 32(2):100-4. PubMed ID: 9039582 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Sevastianova K; Hakkarainen A; Kotronen A; Cornér A; Arkkila P; Arola J; Westerbacka J; Bergholm R; Lundbom J; Lundbom N; Yki-Järvinen H Radiology; 2010 Aug; 256(2):466-73. PubMed ID: 20656836 [TBL] [Abstract][Full Text] [Related]
6. Phosphorus-31 magnetic resonance spectroscopy of the human liver using chemical shift imaging techniques. Cox IJ; Menon DK; Sargentoni J; Bryant DJ; Collins AG; Coutts GA; Iles RA; Bell JD; Benjamin IS; Gilbey S J Hepatol; 1992 Mar; 14(2-3):265-75. PubMed ID: 1323598 [TBL] [Abstract][Full Text] [Related]
7. [In vivo 31-phosphorus magnetic resonance spectroscopy of liver diseases]. Brinkmann G; Melchert U; Förger K; Wunsch-Binder F; Heidemann H; Engemann R Rofo; 1990 Aug; 153(2):204-8. PubMed ID: 2168078 [TBL] [Abstract][Full Text] [Related]
8. [Assessment of functional severity on in vivo hepatic 31P-MRS in diffuse hepatic disease: comparative studies with 99mTc-GSA]. Matoba M; Tonami H; Yokota H; Higashi K; Yamamoto I Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Jul; 60(8):439-44. PubMed ID: 10965750 [TBL] [Abstract][Full Text] [Related]
9. [The relationship between 31P magnetic resonance spectroscopy and the histopathology of livers of chronic viral hepatitis patients]. Wu B; Song B; Zhou XP; Yang Y; Lei XZ; Jiang LL Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):338-41. PubMed ID: 17524264 [TBL] [Abstract][Full Text] [Related]
10. In vivo hepatic 31P magnetic resonance spectroscopy in chronic alcohol abusers. Menon DK; Harris M; Sargentoni J; Taylor-Robinson SD; Cox IJ; Morgan MY Gastroenterology; 1995 Mar; 108(3):776-88. PubMed ID: 7875480 [TBL] [Abstract][Full Text] [Related]
11. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging. Lee JM; Kim CS; Youk JH; Lee MS Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of biochemical metabolites by 31P MR spectroscopy in leukemic infiltration of liver]. Sun JZ; Wang ZK; Yu RS; Huang LS; Xu XF; Zhang MM Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Mar; 39(2):150-6. PubMed ID: 20387242 [TBL] [Abstract][Full Text] [Related]
13. Influence of different fasting periods on P-31-MR-spectroscopy of the liver in normals and patients with liver metastases. Brinkmann G; Melchert UH; Muhle C; Brossmann J; Link J; Reuter M; Heller M Eur Radiol; 1996; 6(1):62-5. PubMed ID: 8797952 [TBL] [Abstract][Full Text] [Related]
14. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times. Kim JH; Kim MJ; Suh SH; Chung JJ; Yoo HS; Lee JT J Magn Reson Imaging; 2002 May; 15(5):573-83. PubMed ID: 11997899 [TBL] [Abstract][Full Text] [Related]
15. [Initial experiences with MR in liver tumors]. Uhlenbrock D; Börsch G; Beyer HK; Schmidt G Rofo; 1985 Aug; 143(2):200-7. PubMed ID: 2992037 [TBL] [Abstract][Full Text] [Related]
16. In vivo P-31-MR-spectroscopy of focal hepatic lesions. Effectiveness of tumor detection in clinical practice and experimental studies of surface coil characteristics and localization technique. Brinkmann G; Melchert UH; Emde L; Wolf H; Muhle C; Brossmann J; Reuter M; Heller M Invest Radiol; 1995 Jan; 30(1):56-63. PubMed ID: 7759218 [TBL] [Abstract][Full Text] [Related]
17. [Changes of 3-tesla 31P-MR spectroscopy of bone and soft tissue tumors]. Qi ZH; Li CF; Ma XX; Li ZF; Zhang K; Yu DX Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):442-6. PubMed ID: 19950555 [TBL] [Abstract][Full Text] [Related]
18. [Spectroscopic imaging of the human liver using 3D CSI: optimization and application in patients with metastatic uvea melanoma]. Beer M; Winkelmann V; Becker JC; Terheyden P; Stenzel M; Bröcker EB; Hahn D; Köstler H Rofo; 2009 Jan; 181(1):60-6. PubMed ID: 19085691 [TBL] [Abstract][Full Text] [Related]
19. Abnormal phosphomonoester signals in 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy. Dixon RM; Angus PW; Rajagopalan B; Radda GK Br J Cancer; 1991 Jun; 63(6):953-8. PubMed ID: 2069850 [TBL] [Abstract][Full Text] [Related]
20. [Clinical application of 31P MRS to malignant liver tumors--with an emphasis on evaluation of response to therapy]. Saeki M; Ashida H; Imamura K; Fukui A; Ishizuka K; Kuwabara M; Wakabayashi M; Ishikawa T; Iwabuchi S; Mizuguchi A Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Jun; 52(6):744-54. PubMed ID: 1322523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]